Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced the launch of Deferasirox Tablets for Oral Suspension, a therapeutically equivalent generic version of Exjade® (deferasirox) Tablets for Oral Suspension, approved by the U.S. Food and Drug Administration (USFDA).
The Exjade® brand had U.S. sales of approximately $113 million MAT for the most recent twelve months ending in September 2019 according to IQVIA Health*.
Dr. Reddy's Deferasirox Tablets for Oral Suspension, are available in 125 mg, 250 mg, and 500 mg dosage strengths in bottle count sizes of 30.
Shares of DR.REDDY's LABORATORIES LTD. was last trading in BSE at Rs.2867.75 as compared to the previous close of Rs. 2878.7. The total number of shares traded during the day was 11422 in over 1046 trades.
The stock hit an intraday high of Rs. 2969 and intraday low of 2850. The net turnover during the day was Rs. 32666464.
Exjade® is a trademark of Novartis Pharma AG.
*IQVIA Retail and Non-Retail MAT September 2019.